ArticleCureus2025
Clinical Impact of POU2F3 Expression in Surgically Resected Pulmonary High-Grade Neuroendocrine Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic values and clinical significance of POU2F3 expression in neuroendocrine carcinomas: a meta-analysis with a focus on small cell lung cancer.Annals of medicine · 2025Pooled it
- Primary cutaneous non neuroendocrine small cell carcinoma POU2F3 subtype: morphologic, immunohistochemical, transcriptomic and methylation analysis of two cases.Virchows Archiv : an international journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHigh-grade neuroendocrine carcinoma (HGNEC) with dominant POU2F3 expression exhibits non-neuroendocrine features. However, clinical data regarding this subset of pulmonary HGNECs are scarce, and its clinical characteristics remain unclear.
methodsClinicopathological data from 109 patients who underwent surgery for HGNEC were collected and analyzed based on transcription factor expression. Patients were divided into a POU2F3-dominant group (HGNEC-P) and a non-dominant group (HGNEC-non-P) according to immunohistochemical analysis. The clinicopathological characteristics of the two groups were compared, and univariate and multivariate analyses were conducted to identify prognostic factors.
resultsThe HGNEC-P group comprised 26 patients, while the HGNEC-non-P group comprised 83 patients. The HGNEC-P group showed significantly lower expression of carcinoembryonic antigen (CEA) (p < 0.001) and a lower rate of vascular invasion (p = 0.021) compared to the HGNEC-non-P group. In addition, the HGNEC-P group exhibited a unique tumor marker profile, with lower serum CEA and higher serum cytokeratin antigen (CYFRA) levels (p < 0.001 and p = 0.046, respectively). Complete resection was achieved in all HGNEC-P cases, whereas only 75.9% of HGNEC-non-P cases achieved complete resection. Multivariate analysis identified POU2F3 expression as an independent prognostic factor for recurrence-free survival (RFS) and disease-specific survival (DSS) (p = 0.037 and p = 0.038, respectively). In patients with pathological Stage I disease, the HGNEC-P group showed significantly better RFS (p = 0.010).
conclusionsPOU2F3-dominant HGNEC is associated with distinct clinicopathological features and favorable prognosis, particularly in early-stage disease. These findings may support the identification of this subset and inform the development of more effective treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.